Lipigon Pharmaceuticals AB signed a research, development, and transfer agreement to acquire antisense drug candidates and patent portfolio of Secarna Pharmaceuticals GmbH & Co KG on March 23, 2020. Going forward, Lipigon will fund and continue the development of the acquired assets and Secarna will receive payments customary for such a transaction. Lipigon Pharmaceuticals AB cancelled the acquisition of antisense drug candidates and patent portfolio of Secarna Pharmaceuticals GmbH & Co KG on March 23, 2021.